Log In
Print
BCIQ
Print
Print this Print this
 

Exenatide-XTEN (VRS-859)

  Manage Alerts
Collapse Summary General Information
Company Amunix Operating Inc.
DescriptionExenatide attached to Amunix's XTEN half-life extension technology for once-monthly dosing
Molecular Target Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R)
Mechanism of ActionGlucagon-like peptide-1 (GLP-1) receptor agonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase I
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes; Treat Type II diabetes and
Regulatory Designation
Partner Diartis Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today